↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "L773:0017 5749 OR L773:1468 3288 ;pers:(Lindberg Greger);lar1:(uu)"

Sökning: L773:0017 5749 OR L773:1468 3288 > Lindberg Greger > Uppsala universitet

Resultat 1-2 av 2

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	Ek, Weronica E, et al. (författare) Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. 2015 Ingår i: Gut. - : BMJ. - 1468-3288 .- 0017-5749. ; 64, s. 1774-1782 Tidskriftsartikel (refereegranskat)abstract IBS shows genetic predisposition, but adequately powered gene-hunting efforts have been scarce so far. We sought to identify true IBS genetic risk factors by means of genome-wide association (GWA) and independent replication studies.
2.	Münch, Andreas, et al. (författare) Low-dose budesonide for maintenance of clinical remission in collagenous colitis : a randomised, placebo-controlled, 12-month trial 2016 Ingår i: Gut. - : BMJ Publishing Group. - 0017-5749 .- 1468-3288. ; 65:1, s. 47-56 Tidskriftsartikel (refereegranskat)abstract Objective: This 1-year study aimed to assess low-dose budesonide therapy for maintenance of clinical remission in patients with collagenous colitis.Design: A prospective, randomised, placebo-controlled study beginning with an 8-week open-label induction phase in which patients with histologically confirmed active collagenous colitis received budesonide (Budenofalk, 9 mg/day initially, tapered to 4.5 mg/day), after which 92 patients in clinical remission were randomised to budesonide (mean dose 4.5 mg/day; Budenofalk 3 mg capsules, two or one capsule on alternate days) or placebo in a 12-month double-blind phase with 6 months treatment-free follow-up. Primary endpoint was clinical remission throughout the double-blind phase.Results: Clinical remission during open-label treatment was achieved by 84.5% (93/110 patients). The median time to remission was 10.5 days (95% CI (9.0 to 14.0 days)). The maintenance of clinical remission at 1 year was achieved by 61.4% (27/44 patients) in the budesonide group versus 16.7% (8/48 patients) receiving placebo (treatment difference 44.5% in favour of budesonide; 95% CI (26.9% to 62.7%), p<0.001). Health-related quality of life was maintained during the 12-month double-blind phase in budesonide-treated patients. During treatment-free follow-up, 82.1% (23/28 patients) formerly receiving budesonide relapsed after study drug discontinuation. Low-dose budesonide over 1 year resulted in few suspected adverse drug reactions (7/44 patients), all non-serious.Conclusions: Budesonide at a mean dose of 4.5 mg/day maintained clinical remission for at least 1 year in the majority of patients with collagenous colitis and preserved health-related quality of life without safety concerns. Treatment extension with low-dose budesonide beyond 1 year may be beneficial given the high relapse rate after budesonide discontinuation.

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-2 av 2

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (2)

Typ av innehåll: refereegranskat (2)

Författare/redaktör: Lindberg, Greger (2)Ta bort avgränsningen; Törnblom, Hans, 1966 (1); Simrén, Magnus, 1966 (1); Talley, Nicholas J. (1); Ohlsson, Bodil (1); Agréus, Lars (1); visa fler...; Hellström, Per M. (1); Andreasson, Anna (1); Burwinkel, Barbara (1); Pedersen, Nancy L (1); Ek, Weronica E (1); Ström, Magnus (1); Karling, Pontus (1); Schmidt, Peter T. (1); Hertervig, Erik (1); Löfberg, Robert (1); Bohr, Johan, 1957- (1); Daly, Mark J. (1); D'Amato, Mauro (1); Tysk, Curt, 1949- (1); Zucchelli, Marco (1); Bresso, Francesca (1); Assadi, Ghazaleh (1); Magnusson, Patrik (1); Münch, Andreas (1); Holliday, Elizabeth ... (1); Walter, Susanna (1); Benoni, Cecilia (1); Dlugosz, Aldona (1); Gazouli, Maria (1); Bellini, Massimo (1); Barbara, Giovanni (1); Camilleri, Michael (1); Björk, Jan (1); Öst, Åke (1); Mueller, Ralph (1); Ripke, Stephan (1); Avnstrøm, Søren (1); Li, Ling (1); Rivera, Natalia V (1); Papadaki, Evangelia (1); Surowy, Harald (1); Reznichenko, Anna (1); Niesler, Beate (1); Houghton, Lesley (1); Karamanolis, George (1); Rappold, Gudrun (1); Rafter, Joseph (1); Gambaccini, Dario (1); Marchi, Santino (1); visa färre...

Lärosäte: Uppsala universitet (2)Ta bort avgränsningen; Linköpings universitet (2); Lunds universitet (2); Karolinska Institutet (2); Göteborgs universitet (1); Umeå universitet (1); visa fler...; Stockholms universitet (1); Örebro universitet (1); visa färre...

Språk: Engelska (2)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy